[1]方向,胡世莲,沈干,等.吉西他滨联合顺铂方案与多西紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的系统评价[J].陆军军医大学学报(原第三军医大学学报),2010,32(21):2347-2351.
 Fang Xiang,Hu Shilian,Shen Gan,et al.Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin:a systematic review[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(21):2347-2351.
点击复制

吉西他滨联合顺铂方案与多西紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的系统评价(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
32卷
期数:
2010年第21期
页码:
2347-2351
栏目:
论著
出版日期:
2010-11-15

文章信息/Info

Title:
Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin:a systematic review
作者:
方向胡世莲沈干吴蕾陈尹孙玉蓓徐婷娟徐维平
安徽医科大学附属省立医院:老年医学科,神经内科,肿瘤科;安徽省循证医学中心
Author(s):
Fang Xiang Hu Shilian Shen Gan Wu Lei Chen Yin Sun Yubei Xu Tingjuan Xu Weiping
Department of Geriatrics,Department of Neurology, Department of Oncology, Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, Anhui Province, 230001;Anhui Evidence based Medicine Center, Hefei, Anhui Province, 230001, China
关键词:
晚期非小细胞肺癌化学治疗吉西他滨多西紫杉醇系统评价
Keywords:
advanced non-small cell lung cancer chemotherapy gemcitabine docetaxel  systematic review
分类号:
R734.2; R969.4; R979.1
文献标志码:
A
摘要:
目的    比较吉西他滨联合顺铂方案(GP)与多西紫杉醇联合顺铂方案(DP)治疗晚期非小细胞肺癌的临床疗效和安全性。    方法      计算机检索Cochrane图书馆(2010年第1期)、Pubmed、CBM、CNKI、万方等数据库;纳入随机对照试验,采用Cochrane系统评价方法进行评价。    结果    共纳入16个研究1 670例晚期非小细胞肺癌患者,16个研究均未详细报道是否采用盲法。DP方案显示出与GP方案相当的中位生存期、中位疾病进展时间、有效率[RR=1.02,95%CI(0.89,1.15)]和生存率[1年RR=1.07,95%CI( 0.93,1.24);2年RR=1.02,95%CI(0.66,1.58)]。15个研究的3~4级毒副作用合并结果显示,GP方案血小板减少、贫血、恶心呕吐发生率高于DP方案[RR=5.22,95%CI(2.97,9.18);RR=1.76,95%CI(1.30,2.38);RR=1.29,95%CI(1.04,1.60)];GP方案白细胞减少及腹泻发生率低于DP方案[RR=0.71,95%CI(0.56,0.89);RR=0.30,95%CI(0.15,0.60)];两方案中性粒细胞减少、虚弱乏力的差异无统计学意义(P>0.05)。    结论      在两方案疗效相近的情况下,选择GP方案或DP方案将取决于药物的毒性及患者的耐受性。
Abstract:
Objective    To compare the effect and safety of gemcitabine (GP) or docetaxel (DP) in combination with cisplatin for advanced non-small cell lung cancer (NSCLC).     Methods     Randomized controlled trials were searched from the Cochrane Library (first issue in 2010), PubMed, CBM, CNKI, and Wanfang databases and evaluated using the Cochrane Collaboration’s software RevMan 5.0.     Results    Sixteen studies involving 1670 patients with NSCLC were included in this study. The blinding method was not reported in these studies. The median survival time, median disease progression time, effective rate (RR=1.02, 95%CI=0.89 and 1.15), and 1- and 2-year survival rates (RR=1.07, 95%CI=0.93 and 1.24; RR=1.02, 95%CI=0.66 and 1.58) of patients with NSCLC were similar for the DP or GP in combination with cisplatin. The incidence of severe (3 to 4 grade) thrombocytopenia (RR=5.22, 95%CI=2.97 and 9.18), anemia (RR=1.76, 95%CI=1.30 and 2.38), nausea and vomiting (RR=1.29, 95%CI=1.04 and 1.60) was higher in combined GP and cisplatin regimen than in combined DP and cisplatin regimen, while the incidence of severe leukocytopenia (RR=0.71, 95%CI=0.56 and 0.89) and diarrhea (RR=0.30,95%CI=0.15 and 0.60) was lower in combined GP and cisplatin regimen than in combined DP and cisplatin regimen.     Conclusion    The effect of the two regimens is similar for advanced NSCLC. The selection of them depends on the toxicity of drugs used and the tolerance of patients.

相似文献/References:

[1]吴国明,钱桂生.晚期非小细胞肺癌EGFR-TKIs治疗的耐药机制研究——挑战中蕴含新的曙光[J].陆军军医大学学报(原第三军医大学学报),2012,34(20):2031.
 Wu Guoming,Qian Guisheng.Drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of advanced non-small cell lung cancer—A new dawn in challenge[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(21):2031.
[2]李彩霞,王凤英,李玉艳,等.小鼠卵巢早衰动物模型的构建[J].陆军军医大学学报(原第三军医大学学报),2008,30(06):506.
 LI Cai-xia,WANG Feng-ying,LI Yu-yan,et al.Establishment of mouse model of premature ovarian failure[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(21):506.
[3]颜芳,傅强.替吉奥胶囊联合多西他赛治疗铂类失败晚期胃癌的临床观察[J].陆军军医大学学报(原第三军医大学学报),2011,33(15):1581.
[4]李莎莎,胡义德.改良PF方案诱导化疗局部晚期鼻咽癌的临床观察[J].陆军军医大学学报(原第三军医大学学报),2011,33(04):414.
 Li Shasha,Hu Yide.Induction chemotherapy efficacy and toxicity of nedaplatin combined tegafur for locally advanced nasopharyngeal carcinoma[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(21):414.
[5]邵克锐,王建春.吉西他滨与紫杉醇联合奈达铂治疗晚期非小细胞肺癌的疗效及毒性反应观察[J].陆军军医大学学报(原第三军医大学学报),2012,34(14):1450.
 Shao Kerui,Wang Jianchun.Efficiency and toxic reaction of nedaplatin combined with gemcitabine or paclitaxel in treatment of advanced non-small cell lung cancer: report of 133 cases[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(21):1450.
[6]张艳玲,胡绍毅,边志衡,等.诱导化疗联合放疗在中晚期鼻咽癌治疗中的临床应用[J].陆军军医大学学报(原第三军医大学学报),2004,26(24):0.[doi:10.16016/j.1000-5404.2004.24.007 ]
 ZHANG Yan-ling,HU Shao-yi,BIAN Zhi-heng,et al.[J].J Amry Med Univ (J Third Mil Med Univ),2004,26(21):0.[doi:10.16016/j.1000-5404.2004.24.007 ]
[7]蒋金妍,边志衡,谢颖,等.PF和PF+新福菌素联合放疗对中晚期鼻咽癌的近期疗效对比[J].陆军军医大学学报(原第三军医大学学报),2004,26(24):0.[doi:10.16016/j.1000-5404.2004.24.015 ]
 JIANG Jin-yan,BIAN Zhi-heng,XIE Yin,et al.[J].J Amry Med Univ (J Third Mil Med Univ),2004,26(21):0.[doi:10.16016/j.1000-5404.2004.24.015 ]
[8]宋娟.颈内静脉置管在183例化疗病人中的应用和护理体会[J].陆军军医大学学报(原第三军医大学学报),2002,24(10):0.[doi:10.16016/j.1000-5404.2002.10.058 ]
[9]李羲,郭先健.mdrl基因表达与肺癌多重抗药性关系的研究[J].陆军军医大学学报(原第三军医大学学报),1995,17(04):0.[doi:10.16016/j.1000-5404.1995.04.002 ]
[10]刘国祥,杨和平,熊玮,等.GP方案治疗50例晚期非小细胞肺癌的疗效观察[J].陆军军医大学学报(原第三军医大学学报),2003,25(18):0.[doi:10.16016/j.1000-5404.2003.18.027 ]
 LIU Guo xiang,YANG He ping,XIONG Wei.[J].J Amry Med Univ (J Third Mil Med Univ),2003,25(21):0.[doi:10.16016/j.1000-5404.2003.18.027 ]

更新日期/Last Update: 2010-11-05